PolyNeuroExchange

Your source for expert information on
symptoms, diagnosis, and treatment options
for Peripheral Neuropathies

CIDP Assessment Tools Infographic

Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) Assessment Tools

CIDP

A number of tools are available to assess disease severity and progression in patients with peripheral neuropathies such as CIDP. Gain a better understanding of four of these tools.

Featured Resource

Overview and Treatment of Multifocal Motor Neuropathy

Claudia Sommer, MD

University of W├╝rzburg, W├╝rzburg, Germany

12:34 MIN

Learn about the diagnosis and treatment of multifocal motor neuropathy

Electrophysiologic Findings In Multifocal Motor Neuropathy

Jonathan S. Katz, MD

Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California

09:15 MIN

Explore electrophysiologic findings of MMN in addition to the classical electrophysiological conduction block

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

13:53 MIN

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

Global Multifocal Motor Neuropathy Quality of Life Patient Survey

Jonathan S. Katz, MD

Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California

09:51 MIN

Examine a quality of life patient study that identifies needs in education and treatment for patients with MMN.

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies

Jeffrey A. Allen, MD

University of Minnesota

12:50 MIN

CIDP
MMN

Review options for individualizing treatment and tools used to assess IgG performance

CIDP Assessment Tools: Grip Strength

Jeffrey A. Allen, MD

University of Minnesota

01:52 MIN

CIDP

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

15:18 MIN

CIDP
GBS

Learn more about the importance of understanding typical and atypical presentations of GBS, including features of clinically distinct variants and subtypes, proper diagnosis, and initiation of appropriate treatment.

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

3:00 MIN

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Fatigue in CIDP

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

09:29 MIN

CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

Wear-Off in IVIG and What it Means in Clinical Practice

Jeffrey A. Allen, MD
Carol L. Koski, MD
Thomas Harbo, MD

16:21 MIN

CIDP

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

SELECT A CHAPTER TO VIEW

Introduction

Introduction to wear-off effects

Monitoring wear-off effects

Combating wear-off effects

Conclusion

CIDP Assessment Tools: INCAT

Jeffrey A. Allen, MD

University of Minnesota

03:32 MIN

CIDP

Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies

SCIg in Multifocal Motor Neuropathy

Hans D. Katzberg, MD, MSc, FRCP(C)

University Health Network /Toronto General Hospital Canada

10:32 MIN

Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

15:31 MIN

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

5:24 MIN

CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

25:18 MIN

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

5:51 MIN

CIDP
GBS

Learn more about how IgG levels and their wear off reflect treatment administration and outcomes in individual IVIG- or SCIG-treated patients with immunodeficiency and peripheral inflammatory neuropathy disorders.

CIDP Assessment Tools: Rasch Overall Disability Score

Jeffrey A. Allen, MD

University of Minnesota

02:15 MIN

CIDP

Hear a brief description of the Rasch version of the Overall Disability Score used in CIDP diagnosis and treatment

CIDP Assessment Tools: Medical Research Council Sum Score

Jeffrey A. Allen, MD

University of Minnesota

02:11 MIN

CIDP

Understand how the Medical Research Council (MRC) Sum Score can be used for evaluating muscle strength in CIDP

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

12:15 MIN

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

12:13 MIN

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

8:25 MIN

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Jeffrey A. Allen, MD

University of Minnesota

12:30 MIN

CIDP

Understand the challenges associated with accurately diagnosing CIDP

GBS and Zika Virus

Kenneth C. Gorson, M.D.

Tufts University School of Medicine

19:15 MIN

Understand the latest information on the Zika Virus and its relationship to Guillain-Barre┬┤ syndrome

Overview and Treatment of Guillain-Barr├® Syndrome (GBS)

David R. Cornblath, MD

Johns Hopkins University, Baltimore, MD, USA

7:23 MIN

Learn more about the features, symptoms, diagnosis, and treatment of GBS.

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

14:01 MIN

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Overview and Treatment of Multifocal Motor Neuropathy

Claudia Sommer, MD

University of W├╝rzburg, W├╝rzburg, Germany

Learn about the diagnosis and treatment of multifocal motor neuropathy

Electrophysiologic Findings In Multifocal Motor Neuropathy

Jonathan S. Katz, MD

Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California

Explore electrophysiologic findings of MMN in addition to the classical electrophysiological conduction block

Pathogenesis and Mechanism of Action of Inflammatory Neuropathies

Richard A. Lewis, MD

Cedars-Sinai Medical Center, Los Angeles, CA, USA

CIDP
GBS
MMN

Find out what pathogenic processes are involved in acute and chronic inflammatory neuropathies, including GBS, CIDP, and MMN.

Global Multifocal Motor Neuropathy Quality of Life Patient Survey

Jonathan S. Katz, MD

Forbes Norris MDA/ALS Research Center at the California Pacific Medical Center in San Francisco, California

Examine a quality of life patient study that identifies needs in education and treatment for patients with MMN.

Optimizing IgG Therapy in Chronic Autoimmune Neuropathies

Jeffrey A. Allen, MD

University of Minnesota

CIDP
MMN

Review options for individualizing treatment and tools used to assess IgG performance

CIDP Assessment Tools: Grip Strength

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Listen to a discussion about Discussing tools that are commonly used to measure grip strength in CIDP

Guillain-Barre Syndrome (GBS): Typical and Atypical Clinical Presentations

Thomas Harbo, MD, PhD

Aarhus University Hospital in Aarhus, Denmark

CIDP
GBS

Subcutaneous Immunoglobulins (SCIg) in Responders to Intravenous Immunoglobulins (IVIg) with Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) and Multifocal Motor Neuropathy (MMN)

Nabil Moumane, MD

Medical Affairs and Pharmacology, CSL Behring

CIDP
MMN

Hear why SCIg may be a better option for long-term treatment of patients on Immunoglobulin therapy with difficult venous access.

Fatigue in CIDP

Karissa Gable, MD

Duke University Medical Center in Durham, North Carolina

CIDP

Engage in a presentation on the comparison between active and remission disease states in CIDP.

Wear-Off in IVIG and What it Means in Clinical Practice

CIDP

Learn about wear-off effects in patients with CIDP, the tools available to monitor them, and the methods to combat them and tailor treatment to the patient.

CIDP Assessment Tools: INCAT

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Learn about the The INCAT scores and variations of them used to evaluate outcome measures for immune-mediated neuropathies

SCIg in Multifocal Motor Neuropathy

Hans D. Katzberg, MD, MSc, FRCP(C)

University Health Network /Toronto General Hospital Canada

Hear the results of a trial to determine the feasibility of switching patients with multifocal motor neuropathy on intravenous to subcutaneous immunoglobulin.

20% Subcutaneous Immunoglobulin for Maintenance Treatment in Chronic Inflammatory Demyelinating Polyneuropathy (PATH): a Randomized, Double-blind, Placebo-controlled, Phase 3 Trial

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Learn about the PATH study results and SCIG (subcutaneous immunoglobulin) treatment in CIDP

Overview and Treatment of Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Learn more about the mechanism of action, symptoms, diagnosis, and treatment of CIDP.

Incidence of GBS and CIDP Following Influenza Vaccination

Peter Donofrio, MD

Vanderbilt University Medical Center, Nashville, TN, USA

CIDP
GBS

Gain an understanding of the existing surveillance data, studies and facts associated with the influenza vaccine as it relates to GBS and CIDP.

IgG Levels and Wear Off Reflect Administration and Outcome

Carol L. Koski, MD

GBS/CIDP Foundation International

CIDP
GBS

CIDP Assessment Tools: Rasch Overall Disability Score

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Hear a brief description of the Rasch version of the Overall Disability Score used in CIDP diagnosis and treatment

CIDP Assessment Tools: Medical Research Council Sum Score

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Understand how the Medical Research Council (MRC) Sum Score can be used for evaluating muscle strength in CIDP

The GRIPPER study: Quantifying IVIG Treatment-Related Fluctuations in CIDP Using Daily Grip Strength Measurements

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Learn more about grip strength as an outcome measure in CIDP and how it is utilized in the Gripper Study as a daily measure of treatment-related fluctuations in IVIg-treated patients.

Restabilization of chronic inflammatory demyelinating polyneuropathy patients with IVIG: restabilization phase of the PATH study

Vera Bril, BSc, FRCPC, MD

University of Toronto,Toronto, Canada

CIDP

Learn about the Restabilization Phase of the PATH Trial with IVIG in CIDP patients

Consistency Over Time of Strength and Disability Measurements in Patients with CIDP on Stable IgG Therapy

Mel Berger, MD, PhD

Medical Research Strategy, CSL Behring

CIDP

Hear the results of a study to understand wear-off effects in CIDP patients during IVIg therapy.

Improving CIDP Diagnosis: The Challenges of Under and Over Diagnosis

Jeffrey A. Allen, MD

University of Minnesota

CIDP

Understand the challenges associated with accurately diagnosing CIDP

GBS and Zika Virus

Kenneth C. Gorson, M.D.

Tufts University School of Medicine

Understand the latest information on the Zika Virus and its relationship to Guillain-Barre┬┤ syndrome

Overview and Treatment of Guillain-Barr├® Syndrome (GBS)

David R. Cornblath, MD

Johns Hopkins University, Baltimore, MD, USA

Learn more about the features, symptoms, diagnosis, and treatment of GBS.

Dosing Schedules for IVIg: The Use of an Algorithm as a Suggestion for Personalized Dosing

Michael Lunn, PhD

National Hospital for Neurology and Neurosurgery, Queen Square, London

CIDP

Learn how an algorithm could be used to personalize dosing schedules for IVIg.

Video Library

NOW PLAYING